21 results
8-K
EX-2.4
LSTA
Lisata Therapeutics Inc
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
security that might be required of Caladrius with respect thereto. This Lock-Up Agreement and any claim, controversy or dispute arising under
8-K
EX-10.2
LSTA
Lisata Therapeutics Inc
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
conflict of laws provisions. Except with respect to injunctive relief, any dispute, claim or controversy arising out of this Agreement (“Dispute
8-K
EX-2.1
LSTA
Lisata Therapeutics Inc
14 Jul 11
Entry into a Material Definitive Agreement
12:00am
of any and all liability with respect to the matter in controversy, unless (i) such claim or demand seeks an order, injunction or other equitable relief … with respect to the matter in controversy.
Section 8.4 Escrow Account. Upon approval of this Agreement the Amorcyte Stockholders shall be deemed to have
425
EX-2.1
fheuuc8
14 Jul 11
Business combination disclosure
12:00am
425
EX-10.2
3ba d9482zw9x
16 Nov 10
Business combination disclosure
12:00am
8-K
EX-10.2
fq6 jnnkbk
16 Nov 10
NeoStem Announces Pricing of Concurrent
12:00am
425
EX-2.1
qpgmkeyt3 ryiu
23 Sep 10
Business combination disclosure
12:00am
8-K
EX-2.1
xypprqpf2qv3ck73l
23 Sep 10
NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
12:00am
8-K
EX-99.1
bkyv9 ca3mwh
28 Feb 07
Regulation FD Disclosure
12:00am
8-K
EX-10.4
xwwfxthv6ckimdjkdp
1 Feb 07
Departure of Directors or Principal Officers
12:00am
8-K
EX-10.4
j1oti2
8 Jun 06
Entry into a Material Definitive Agreement
12:00am
8-K
uqjn4jwhxqpdgiw 9k1
25 Apr 05
Unregistered Sales of Equity Securities
12:00am
8-K
EX-10.3
va4ag499
16 Sep 04
Unregistered Sales of Equity Securities
12:00am